SHSE:600566'
s ROE % Range Over the Past 10 Years
Min: 12.06 Med: 22.05 Max: 34.16
Current: 12.06
During the past 13 years, Hubei Jumpcan Pharmaceutical Co's highest ROE % was 34.16%. The lowest was 12.06%. And the median was 22.05%.
SHSE:600566's ROE % is ranked better than 70.8% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs SHSE:600566: 12.06
Hubei Jumpcan Pharmaceutical Co (SHSE:600566) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Hubei Jumpcan Pharmaceutical Co ROE % Related Terms
Hubei Jumpcan Pharmaceutical Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hubei Jumpcan Pharmaceutical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hubei Jumpcan Pharmaceutical Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hubei Jumpcan Pharmaceutical Co's ROE % distribution charts can be found below:
* The bar in red indicates where Hubei Jumpcan Pharmaceutical Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Hubei Jumpcan Pharmaceutical Co (SHSE:600566) has a ROE % of 10.82% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. This is 51% below median its historical median of 22.05. Over the past decade, Hubei Jumpcan Pharmaceutical Co's ROE % has ranged from 12.06 to 34.16. According to the industry distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #273 out of 935 companies in the Drug Manufacturers industry, placing it in the top 29.2%.
Is Hubei Jumpcan Pharmaceutical Co's ROE % too high?
Hubei Jumpcan Pharmaceutical Co's current ROE % of 10.82% is 51% below median its 10-year median of 22.05. Over the past 10 years, this metric has ranged from a low of 12.06 to a high of 34.16. The Drug Manufacturers industry median ROE % is 6.00. Hubei Jumpcan Pharmaceutical Co's value of 10.82% is 80.3% above this industry median. Based on the distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #273 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hubei Jumpcan Pharmaceutical Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hubei Jumpcan Pharmaceutical Co's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #273 out of 935 companies for ROE %. This puts Hubei Jumpcan Pharmaceutical Co in the upper half of its industry. The industry median ROE % is 6.00. Hubei Jumpcan Pharmaceutical Co's value of 10.82% is 80.3% above this benchmark. Historically, Hubei Jumpcan Pharmaceutical Co's own ROE % has ranged from 12.06 to 34.16 over the past decade. While the company's 10-year median is 22.05 vs. the industry median of 6.00, Hubei Jumpcan Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hubei Jumpcan Pharmaceutical Co's current ROE % of 10.82% is 80.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hubei Jumpcan Pharmaceutical Co's current ROE % is 10.82%, which is 51% below median its own 10-year median of 22.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hubei Jumpcan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co (SHSE:600566) is currently considered Fairly Valued. The stock's GF Value™ is ¥20.92, compared to a current price of ¥22.47 — trading 7.4% above its estimated fair value. The current ROE % is 10.82%, which is 51% below median its 10-year median of 22.05 and 80.3% above the Drug Manufacturers industry median of 6.00. Hubei Jumpcan Pharmaceutical Co's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Hubei Jumpcan Pharmaceutical Co (SHSE:600566), the current ROE % is 10.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Overvalued in 2026?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥22.47 is trading 7.4% above its estimated GF Value™ of ¥20.92.
GuruFocus considers Hubei Jumpcan Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600566:
ROE %: 10.82% (51% below median its 10-year median of 22.05)
GF Value™: ¥20.92 vs. price of ¥22.47 (7.4% above fair value)
Industry Position: 80.3% above the Drug Manufacturers median (#273 of 935)
No single metric tells the full story. See the SHSE:600566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hubei Jumpcan Pharmaceutical Co Business Description
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumonology, gastroenterology, and geriatrics. The company also develops Chinese and Western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
87GF Score
Get the complete analysis for SHSE:600566
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600566 has been successfully added to your 
